Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ENSC vs CELU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENSC Captures Overall Composite Edge (53.4 HOLD vs 42.9 HOLD), While CELU Leads 4–1 on Growth & Valuation Pillars
ENSC Overall Winner
6-Pillar Tally: ENSC 1 – 4 CELU (1 Tie)
Matrix Metrics: ENSC 6 – 3 CELU
As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (53.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–3 (led by Valuation Multiples), while CELU wins 4–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin).
- Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. CELU 42.9/100 HOLD) and 0.98β · 79% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ENSC vs CELU
ENSC
Head-to-Head Winner
Ensysce Biosciences, Inc. Common Stock
$0.36
-0.17% 1D
Market Cap
$7.0M
TTM Revenue
$4.5M
Forward P/E
0.8x
Beta / 30D Vol
0.98β · 79% Vol
Unified Composite Score
53.4
HOLD
Tech 50.0
Fund 62.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
CELU
Celularity Inc. Class A Common Stock
$0.46
-1.05% 1D
Market Cap
$15.2M
TTM Revenue
$19M
Forward P/E
N/M
Beta / 30D Vol
2.01β · 135% Vol
Unified Composite Score
42.9
HOLD
Tech 25.0
Fund 48.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ENSC 1 – 4 CELU)
1. Valuation Multiples
ENSC
Forward P/E
0.8x
N/M
Trailing P/E
0.8x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
1.4x
2.7x
2. Growth & Scale
CELU
Revenue Growth (YoY)
-15.1%
-5.3%
Earnings Growth (YoY)
+0.0%
-61.3%
TTM Revenue (USD)
$4.5M
$19M
Market Cap
$7.0M
$15.2M
3. Profitability & Quality
CELU
Gross Margin
N/A
19.2%
Operating Margin
-281.3%
-254.0%
Net Profit Margin
-280.5%
-245.7%
Return on Equity (ROE)
-1295.1%
-6367.2%
4. Balance Sheet & Cash Flow
CELU
Cash Generation (TTM)
-$9.7M
-$8.9M
Cash Flow Margin
N/A
-47.8%
Net Cash / Leverage
-$499,633 Net Debt
$35M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CELU
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
116.6% (50th %ile)
Put/Call OI Skew
N/A
3.60x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ENSC (6) vs CELU (3)| Institutional Metric | ENSC | CELU | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $7.0M | $15.2M | Tie | |
| Trailing P/E Ratio | 0.8x | N/M | ENSC | |
| Forward P/E Ratio | 0.8x | N/M | ENSC | |
| Revenue Growth (YoY) | -15.1% | -5.3% | CELU | |
| Operating Margin (TTM) | -281.3% | -254.0% | CELU | |
| Net Profit Margin | -280.5% | -245.7% | CELU | |
| Return on Equity (ROE) | -1295.1% | -6367.2% | ENSC | |
| 52-Week Range Position | 8% ($0–$2) | 2% ($0–$3) | ENSC | |
| Beta / 30D Volatility | 0.98β · 79% Vol | 2.01β · 135% Vol | ENSC | |
| Unified Institutional Score | 53.4 / 100 (HOLD) | 42.9 / 100 (HOLD) | ENSC | |
| Trailing 12M Revenue (USD) | $4.5M | $19M | Scale | |
| Gross Profit Margin (TTM) | N/A | 19.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.4x EV/Rev | N/M PEG · 2.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$9.7M (-$499,633 Net Debt) | -$8.9M ($35M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ENSC +26.35 pp
3M Horizon
ENSC +39.96 pp
6M Horizon
ENSC +59.78 pp
1Y Horizon
CELU +7.73 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENSC Revenue | CELU Revenue | ENSC Op. Margin | CELU Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | $10M | -41.0% | -1064.0% | ENSC |
| FY2021 | $0M | $20M | -562.7% | -511.2% | CELU |
| FY2022 | $0M | $20M | -959.9% | -142.4% | CELU |
| FY2023 | $0M | $20M | -480.5% | -844.4% | ENSC |
| FY2024 | $10M | $50M | -129.2% | -70.7% | CELU |
| FY2025 | $10M | $30M | -202.1% | -230.9% | ENSC |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ENSC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CELU
BREAKDOWN
Current IV
116.6%
IV Percentile
50th %ile
Put/Call OI Skew
3.60x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ENSC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CELU Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ENSC vs CELU Key Questions & Quantitative Answers
As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (53.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–3 (led by Valuation Multiples), while CELU wins 4–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin). Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. CELU 42.9/100 HOLD) and 0.98β · 79% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CELU leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENSC cumulative revenue shifted +0.0% while CELU shifted +200.0%. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.
ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus CELU (-6367.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CELU vs ENSC · Reverse Pair
ENSC vs QNRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal